BOSTON--(BUSINESS WIRE)--Jan 6, 2026--
Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of its biopharma business. Building on its successful collaborations in late-stage biomarker development, Ibex is now extending its platform into earlier translational research, biomarker development, and trial-efficiency optimization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106469089/en/
Ibex’s high-performance AI platform—already deployed across more than 50 health systems worldwide and used in collaboration with major industry organizations such as Philips and Roche —now supports exploratory, preclinical, and clinical evidence generation, while providing a seamless foundation for future companion diagnostic (CDx) programs.
"In an era where modalities like antibody-drug conjugates (ADC), immune-modulating agents, and molecularly guided therapies are reshaping oncology, the field needs biomarkers that match the complexity of our treatments and enable adequate patient selection”, says Paolo Tarantino, M.D., Research and Clinical Fellow at Dana-Farber Cancer Institute and Harvard Medical School. “AI-based biomarker platforms can integrate multiple dimensions of cancer biology in a rapid, objective, and reliable way, offering a terrific opportunity to enhance treatment tailoring. This platform has the potential to transform both early and late drug development, further accelerating drug development and ensuring precision in oncology."
New Analytical Modules
Ibex will be introducing new and expanded AI modules relevant to high-priority therapeutic areas, such as:
These modules are developed under ISO 13485-aligned design control, in an IVD-ready architecture, and supported by fully versioned pipelines and audit trails that meet global regulatory expectations.
“Pharma needs partners that can support biomarker innovation from the earliest exploratory work to fully regulated CDx programs. With our proven execution in late-stage development including FDA and CE-IVDR clearances, and as we strengthen our translational capabilities, we are uniquely positioned to accelerate drug development pipelines and improve evidence quality worldwide,” remarks Joseph Mossel, Co-Founder & CEO, Ibex Medical Analytics.
A Platform Built for Security, Scale, and Global Deployment
With next-generation enterprise security, validated through detailed big-pharma due diligence—including IT security, supplier risk, and privacy assessments, the system can be deployed in dedicated virtual private clouds, on-prem, hybrid, or air-gapped environments and is compatible with leading WSI scanners, DICOM-DP infrastructure, HL7/FHIR workflows, and structured outputs for regulated trial endpoints.
Learn more at: https://ibex-ai.com/biopharma/
About Ibex Medical Analytics
Ibex is a global leader in clinical-grade AI for pathology, with deployed solutions in over 50 health systems and partnerships spanning life-science companies, reference laboratories, and digital pathology vendors. Ibex’s platform supports biomarker discovery, clinical trial efficiency, and CDx-ready evidence generation, backed by an ISO 13485-compliant QMS.
The Ibex platform includes solutions that are CE-IVD certified and registered with the UK MHRA, TGA in Australia and ANVISA in Brazil. It includes a solution that is FDA cleared and others that are Research Use Only (RUO) in the United States.
Ibex's platform now extends to earlier translational research, biomarker development, and trial-efficiency optimization
MADRID (AP) — Anastasia Potapova dropped to her knees, put both hands on her face and started crying.
The “explosion of emotions inside” came after the 56th-ranked Austrian became the first “lucky loser” to reach a WTA 1000 semifinal by defeating Karolina Pliskova 6-1, 6-7 (4), 6-3 on Wednesday at the Madrid Open.
She almost gave up the victory, squandering three match points in the second set and having to overcome a 1-3 deficit in the decisive set.
“I (had) a few match points in the second set, on serve, but I couldn't manage my nerves at that time,” the 25-year-old Potapova said. “It seems that this tournament keeps giving me second chances and I keep using them. So yeah, supper happy.”
The Russian-born Potapova said she got a huge boost when her boyfriend, Dutch player Tallon Griekspoor, arrived to watch.
“I was a little bit gone mentally in the third set. I didn’t believe in myself at that moment,” she said. “But big respect to my boyfriend who came just on time. He saved me. He kept telling me, ‘You can do this, we are all together here, just keep going.’”
Potapova said Griekspoor is “not scared” of telling her anything and deserved some credit for her victory.
“I just played, and mentally he kept me there,” she said. “It just happened at the such important moment, and it gave me a lot of energy. Mentally, I think he got this match. I did it physically. He did it mentally."
She will face either Linda Noskova or Marta Kostyuk for a spot in the final.
Potapova got into the main draw as a lucky loser despite losing her second qualifying match in Madrid. She became the first lucky loser to reach a WTA 1000 or Tier I semifinal since the Tier format’s inception in 1990, according to the WTA.
Potapova went on to win four straight matches, including against world No. 2 Elena Rybakina in the round of 16.
“To be honest, I didn’t expect myself being in the draw again because at first they didn’t take my name as a lucky loser,” she said. “And then the days kept on going and nobody was injured or pulling out. Then the last moment I got the information, literally 30 minutes before the match, that I was given a chance to step on court here again.”
She said she had been just enjoying “some nice days” in the Spanish capital, with no expectations.
“Maybe that’s the key, you don’t need to be always so zoomed in and so locked in on the tournament,” Potapova said. “Maybe it’s just a matter of sometimes just enjoy yourself and enjoy the journey, and maybe that’s how the results can also come.”
She said it feels like “a miracle” to have made it all the way to the semifinals.
"It’s pretty rare when you get the second chance and that you go almost all the way until the end,” Potapova said. “But also at the same time I always say, if you got it, maybe you deserved it. So I did work hard. Also, you know, anyone can get a second chance, but how many of those will actually take it? So I’m happy that I didn’t waste it, and I was able to convert it and to be here now.”
AP tennis: https://apnews.com/hub/tennis
Karolina Pliskova of the Czech Republic reacts during her match against Anastasia Potapova of Russia during the Madrid Open tennis tournament in Madrid, Wednesday, April 29, 2026. (AP Photo/Pablo Garcia)
Anastasia Potapova of Russia returns the ball to Karolina Pliskova of the Czech Republic during the Madrid Open tennis tournament in Madrid, Wednesday, April 29, 2026. (AP Photo/Pablo Garcia)
Anastasia Potapova of Russia reacts during her match against Karolina Pliskova of the Czech Republic during the Madrid Open tennis tournament in Madrid, Wednesday, April 29, 2026. (AP Photo/Pablo Garcia)
Anastasia Potapova of Russia reacts during her match against Karolina Pliskova of the Czech Republic during the Madrid Open tennis tournament in Madrid, Wednesday, April 29, 2026. (AP Photo/Pablo Garcia)
Anastasia Potapova of Russia returns the ball to Karolina Pliskova of the Czech Republic during the Madrid Open tennis tournament in Madrid, Wednesday, April 29, 2026. (AP Photo/Pablo Garcia)
